MarketLens
Sign Up

Qiagen's Automation Pipeline: A Hidden Catalyst for a 2027 Rebound

3 months ago
SHARE THIS ON:

Qiagen's Automation Pipeline: A Hidden Catalyst for a 2027 Rebound

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•4 days ago

How to Invest in AI Drug Discovery

Danaher plans to launch its first AI-powered autonomous laboratory at commercial scale in early 2027, though the stock barely moved on the announcement date. The move marks a quiet turning point for l...
Stock News•2 months ago

Alamar Biosciences: Promising But Expensive Proteomics Growth

Alamar Biosciences' ARGO platform converts instrument placements into recurring consumables demand, with consumables growing faster than instruments. Profitability of this growth remains unproven as t...
Stock News•3 months ago

Qiagen: New Launches Signal A Turnaround

Qiagen's new product launches and automation initiatives are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launch...

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Stock News•1 hour ago

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•7 hours ago

Should You Invest in the S&P 500 Right Now or Wait? There's 1 Clear Answer

Stock News•7 hours ago

1 Analyst Thinks Alphabet Stock Could Jump 20% on AI Chip Demand. Is He Right?

Stock News•8 hours ago

Bronstein, Gewirtz & Grossman LLC Urges Alphabet Inc. Investors to Act: Class Action Filed Alleging Investor Harm